#USA #New York #GLP-1 Medications #Hello Dose #Bracha Banayan

A Deep Dive into GLP-1 Medications with Bracha Banayan

Bracha Banayan, a recognized nurse practitioner and founder of Hello Dose, has launched an enlightening book titled "Why Are You Still Hungry?". This book is tailored for individuals currently on, considering, or recovering from cycles of eating-related struggles linked to GLP-1 medications. Banayan seeks to reshape the narrative around weight struggles, challenging the pervasive myth that they are purely a result of willpower failures.

In her new paperback, available on platforms like Amazon and Apple Books, Banayan discusses the underlying biological factors that complicate weight management, such as insulin resistance and the body's set point. She elaborates on the phenomenon known as 'food noise', which refers to the continuous and often intrusive thoughts about food experienced by many. Banayan breaks down how GLP-1 and GIP receptor agonist medications, including semaglutide and tirzepatide, interact not just with bodily systems but also with cognitive processes in the brain.

Importantly, the book does not regard medication as a simple 'quick fix'. Instead, it presents GLP-1 therapy as one element in a greater strategy that emphasizes behavioral changes. Banayan introduces her innovative DROP™ Method, which encompasses four key elements: 1) Dosing, 2) Real-time feedback, 3) Owning your habits, and 4) The Pause factor. The method aims to enhance accountability and promote a thorough understanding of one's personal health journey.

Furthermore, Banayan addresses side-effect management, encouraging readers to communicate openly with healthcare professionals about proper dosing. She touches upon the stigma often linked with weight-loss medications, as many patients face guilt or shame in their journeys. The latter chapters delve into the emotional and psychological aspects of forming a healthier relationship with food and breaking free from negative cycles.

Bracha Banayan's perspective on this issue is particularly compelling given her own journey. Originally skeptical about GLP-1 medications, she once advised patients to follow conventional wisdom of